A comprehensive view of Viiv Healthcare Ltd.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

European Medicines Agency validates ViiV Healthcare's marketing authorisation application for cabotegravir long-acting injectable for HIV Prevention

ViiV Healthcare announces recipients of largest philanthropic fund in the US dedicated to HIV prevention for Black women; 17 groups awarded grants to raise awareness, connect women to HIV care, drive narrative change among providers

ViiV Healthcare announces FDA approval of Triumeq PD, a dispersible single-tablet treatment regimen for children living with HIV-1

ViiV Healthcare, Janssen Pharmaceutical receive FDA approval for label update for Cabenuva cabotegravir, non-nucleoside reverse transcriptase inhibitor rilpivirine injectable to treat HIV-1; approved dose is once-monthly or once every two months

GSK announces settlement regarding patent infringement litigation between GSK, Shionogi and Gilead Sciences regarding ViiV Healthcare’s patents relating to HIV drug dolutegravir; Gilead will pay US$1.25B upfront to ViiV Healthcare in Q1 2022

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count